Friday, July 24, 2020 5:41:43 PM
What's Nasrat's incentive for getting MIKAHs half of Adderall sales to Elite.
Having half of Adderall sales (MIKAH) is a comfortable income without ever getting rid of Elite.
We were going to get into this next week, but as usual, NASDAQ pushes the envelope. Let's discuss.
Nasrat says he hopes Elite gets full ownership of the Adderall ANDA's, and I believe him. In terms of a buyout, Nasrat would want 100% of Adderall $$ recorded as Elite revenue, which then would enjoy the magical multiplication benefits of the PE ratio. But here's the wrinkle- he can do it at the last minute and still get the full benefit. I guarantee when Nasrat does get around to letting Elite have that revenue, it will be a split second before the start of a fiscal year. Until then, it is to Nasrat's benefit to let his baby MIKAH continue to suckle at the Adderall teet. MIKAH grows fat and strong, helping out Elite whenever possible with a discarded ANDA at "friend" prices, on credit. Meanwhile, Elite continues to languish without enough revenue to support even a dime of share price, for years on end. Shareholder dilution continues to support limited R&D budgets. Concerta delayed for 1 year, 2 years, 3... Elite stays weak and gimpy until Nasrat says otherwise.
Why should Nasrat get to personally benefit from Adderall while Elite shareholders sit in a ditch hoping for scraps? I can understand why Nasrat hates me, but why does Nasrat hate NASDAQ?
If you don't care about the share price, then stop reading. If you do care about SP, then we need all the income we can get. It's too late to save the opioid ANDA's from Nasrat's deranged pruning spree, but it's not too late to save the Adderalls. The sooner the better. I'm going to try to do something about it. In the end, I may be powerless to affect real change, but that doesn't mean I shouldn't try. I'll at least know I stood up for myself. It's time to expect better from Elite management.
Thanks for reading. More to come...
Occam's razor: the simplest solution is most likely the right one.
Hanlon's razor: never attribute to malice that which is adequately explained by stupidity.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
